Angiodynamics Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:5em;'>A</div>
ANGO -- USA Stock  

USD 23.93  0.30  1.24%

Angiodynamics Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 257.22 Million. Working Capital is expected to rise to about 129.2 M this year, although the value of Net Income Per Employee will most likely fall to (245.4 K). Angiodynamics is scheduled to announce its earnings today. The next earnings report is expected on the 15th of July 2021. As some conservatives are trying to avoid healthcare space, we'll outline Angiodynamics a little further and explain its current market possibilities. We will evaluate why we are still confident in anticipation of a recovery. Angiodynamics barely shadows the market. We can now inspect Angiodynamics as a potential investment option for your portfolios.
Published over two weeks ago
View all stories for Angiodynamics | View All Stories
Does Angiodynamics (NASDAQ:ANGO) have persistent technical and fundamental indicators based on the latest rise?
Our investment recommendation module complements current analysts and expert consensus on Angiodynamics. It analyzes the firm potential to grow using all fundamental, technical, and market related data available at the time.
This firm dividends can provide a clue to the current value of the stock. Angiodynamics is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Angiodynamics income statement, its balance sheet, and the statement of cash flows. Potential Angiodynamics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Angiodynamics investors may use each financial statement separately, they are all related. The changes in Angiodynamics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Angiodynamics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Angiodynamics fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Angiodynamics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Angiodynamics shares is the value that is considered the true value of the share. If the intrinsic value of Angiodynamics is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Angiodynamics.
Please read more on our fundamental analysis page.

What is Angiodynamics Asset Breakdown?

Angiodynamics reports assets on its Balance Sheet. It represents the amount of Angiodynamics resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Angiodynamics volatility, please check the breakdown of all its fundamentals

Are Angiodynamics Earnings Expected to grow?

The future earnings power of Angiodynamics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Angiodynamics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Angiodynamics stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Angiodynamics expected earnings.

Angiodynamics Gross Profit

Angiodynamics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Angiodynamics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Angiodynamics Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Exercise or conversion by Stephen Trowbridge of 13625 shares of Angiodynamics subject to Rule 16b-3

Legal trades by Angiodynamics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Angiodynamics insider trading alert for exercise of non-qualified stock option (right to buy) by Stephen Trowbridge, EVP and CFO, on 16th of April 2021. This event was filed by Angiodynamics Inc with SEC on 2021-04-16. Statement of changes in beneficial ownership - SEC Form 4. Stephen Trowbridge currently serves as sr. vp, general counsel and assistant secretary of Angiodynamics [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Angiodynamics Investor Appetite?

Institutional investors typically avoid acquiring a high percentage of Angiodynamics stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Angiodynamics is distributed among investors.

Ownership Allocation

Angiodynamics retains a total of 37.96 Million outstanding shares. The majority of Angiodynamics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Angiodynamics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Angiodynamics. Please pay attention to any change in the institutional holdings of Angiodynamics as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.


Institutions
96.94%
Retail Investors-0.13
Insiders3.19
Institutions96.94

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Angiodynamics has an asset utilization ratio of 37.33 percent. This suggests that the company is making $0.37 for each dollar of assets. An increasing asset utilization means that Angiodynamics is more efficient with each dollar of assets it utilizes for everyday operations.


Assets Non Current
562.4 M
Goodwill
498 M
Current Assets192.81 Million15.38
Assets Non Current562.42 Million44.85
Goodwill498.02 Million39.71
Tax Assets727,8630.058

How will Angiodynamics institutional investors react to the next slide?

Latest jensen alpha is at 0.64. Angiodynamics currently demonstrates below-average downside deviation. It has Information Ratio of 0.19 and Jensen Alpha of 0.64. However, we advise investors to further question Angiodynamics expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Angiodynamics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Angiodynamics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Angiodynamics

Whereas many other companies in the medical instruments & supplies industry are either recovering or due for a correction, Angiodynamics may not be performing as strong as the other in terms of long-term growth potentials. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to drop some or all of your Angiodynamics holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Angiodynamics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Angiodynamics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com